Roche Holding Feed

	Est. tid*
2025-07-24	N/A	Kvartalsrapport 2025-Q2
2025-03-27	-	X-dag ordinarie utdelning RO 9.70 CHF
2025-03-27	-	X-dag ordinarie utdelning ROG 9.70 CHF
2025-03-25	-	Årsstämma
2025-01-30	-	Bokslutskommuniké 2024
2024-03-14	-	X-dag ordinarie utdelning RO 9.60 CHF
2024-03-14	-	X-dag ordinarie utdelning ROG 9.60 CHF
2024-03-12	-	Årsstämma
2023-03-16	-	X-dag ordinarie utdelning RO 9.50 CHF
2023-03-16	-	X-dag ordinarie utdelning ROG 9.50 CHF
2022-03-17	-	X-dag ordinarie utdelning RO 9.30 CHF
2022-03-17	-	X-dag ordinarie utdelning ROG 9.30 CHF
2022-03-15	-	Årsstämma
2021-11-26	-	Extra Bolagsstämma
2021-03-18	-	X-dag ordinarie utdelning RO 9.10 CHF
2021-03-18	-	X-dag ordinarie utdelning ROG 9.10 CHF
2021-03-16	-	Årsstämma
2020-03-19	-	X-dag ordinarie utdelning RO 9.00 CHF
2020-03-19	-	X-dag ordinarie utdelning ROG 9.00 CHF
2020-03-17	-	Årsstämma

2025-06-30 07:00:00 Changes to the Roche Enlarged Corporate Executive Committee 261,90 CHF | -0,55%

2025-06-23 07:00:00 Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

2025-06-20 17:45:00 Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma 260,80 CHF | +1,40%

2025-06-16 07:00:00 Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease 263,85 CHF | -2,17%

2025-06-15 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

2025-06-04 07:00:00 Roche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) 268,10 CHF | +1,02%

2025-06-03 07:00:00 Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer 265,40 CHF | +0,04%

2025-05-31 14:05:00 New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

2025-05-30 07:00:00 Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis 264,00 CHF | +1,11%

2025-05-23 15:00:00 CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer 257,00 CHF | -0,45%

2025-05-23 07:10:00 Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology 257,00 CHF | -0,45%

2025-05-23 07:00:00 New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients 257,00 CHF | -0,45%

2025-05-22 17:45:00 FDA approves Roche’s Susvimo for diabetic retinopathy 257,00 CHF | -0,45%

2025-05-20 20:40:00 Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma 262,65 CHF | -1,00%

2025-05-14 22:00:00 Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis 253,40 CHF | -1,71%

2025-05-13 07:00:00 Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer 260,50 CHF | +0,72%

2025-05-06 07:00:00 Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity 272,20 CHF | +0,04%

2025-04-30 07:00:00 CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings 269,00 CHF | +0,73%

2025-04-25 07:00:00 New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission 261,10 CHF | -0,15%

2025-04-23 07:00:00 Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS) 258,45 CHF | +1,95%

2025-04-22 07:00:00 Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years 253,50 CHF | -0,98%

2025-04-14 07:00:00 European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy 249,00 CHF | +2,83%

2025-04-03 15:30:00 Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025 278,15 CHF | -2,16%

2025-04-02 17:45:00 Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis 278,15 CHF | -2,16%

2025-03-25 13:30:00 Roche Generalversammlung 2025 305,30 CHF | +0,81%

2025-03-25 13:30:00 Assemblée générale 2025 de Roche 305,30 CHF | +0,81%

2025-03-25 13:30:00 Roche Annual General Meeting 2025 305,30 CHF | +0,81%

2025-03-17 07:00:00 Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference 310,45 CHF | +1,95%

2025-03-12 07:00:00 Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity 306,55 CHF | +3,25%

2025-03-07 07:00:00 Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston 307,15 CHF | +2,04%

2025-03-05 07:00:00 FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis 301,80 CHF | -0,15%

2025-03-02 23:00:00 Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies 300,40 CHF | +1,08%

2025-02-28 14:15:00 CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma 297,20 CHF | -0,35%

2025-02-20 19:30:00 Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology 297,50 CHF | +2,15%

2025-02-12 17:45:00 FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA) 297,80 CHF | +2,87%

2025-02-07 09:45:00 New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis 289,90 CHF | +0,96%

2025-02-04 17:45:00 FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness 287,35 CHF | +0,86%

2025-01-31 17:45:00 Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU 284,20 CHF | -0,59%

2025-01-30 07:00:00 [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum 285,90 CHF | +1,85%

2025-01-30 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth 285,90 CHF | +1,85%

2025-01-29 07:00:00 Change to the Roche Enlarged Corporate Executive Committee 280,70 CHF | +0,30%

2025-01-28 07:00:00 Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer 279,85 CHF | +0,18%

2025-01-27 07:00:00 Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD) 279,35 CHF | +1,64%

2025-01-22 07:00:00 Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care 274,75 CHF | +3,19%

2025-01-08 07:10:00 Roche purchases shares in tender offer for Poseida Therapeutics, Inc. 264,90 CHF | +1,34%

2024-12-19 07:00:00 Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease 247,55 CHF | -3,71%

2024-12-18 07:00:00 Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution 257,10 CHF | -0,08%

2024-12-13 07:10:00 Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness 254,45 CHF | +0,49%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Roche Holding

Kalender

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden